CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aclaris Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aclaris Therapeutics Inc
701 Lee Road, Suite 103
Phone: (484) 324-7933p:484 324-7933 WAYNE, PA  19087  United States Ticker: ACRSACRS
Business Summary
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board, President, Interim Chief Executive Officer, Co-Founder Neal S.Walker 53 1/17/2024 7/1/2012
Chief Financial Officer KevinBalthaser 36 1/1/2023 1/1/2023
Chief Scientific Officer JosephMonahan 67 1/1/2021 8/1/2017
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ACLARIS THERAPEUTICS INTERNATIONAL LIMITED 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM UK
Confluence Life Sciences, Inc. 4320 Forest Park Avenue St. Louis MO United States

Business Names
Business Name
Aclaris Life Sciences, Inc.
ACRS
Confluence Discovery Technologies, Inc.

General Information
Number of Employees: 91 (As of 12/31/2023)
Outstanding Shares: 70,925,042 (As of 1/31/2024)
Shareholders: 49
Stock Exchange: NASD
Federal Tax Id: 460571712
Fax Number: (302) 655-5049
Email Address: info@vicepttx.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024